#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16864	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2066	808.4	0	.	n	.	0	C451T	SNP	451	451	C	680	680	T	1051	T,C,A	994,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16864	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2066	808.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1413	1413	C	912	C	856	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16864	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2066	808.4	0	HET	.	.	.	C207T	.	207	207	C	436	436	C	942	C,T	717,150	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29964	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3603	828.5	0	.	n	.	0	T695C	SNP	695	695	T	1024	1024	C	950	C,T	881,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29964	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3603	828.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2300	2300	C	956	C,T,G	874,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29964	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3603	828.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2374	2374	A	1007	A	944	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29964	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3603	828.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2926	2926	C	873	C	820	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1934	folP	855	855	100.0	folP.l15.c4.ctg.1	1664	116.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1106	1108	AGC	216;218;218	A;G;C	205;205;201	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5856	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3524	165.6	1	SNP	p	S91F	1	.	.	271	273	TTC	638	640	TTC	227;224;227	T;T;C	211;210;211	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5856	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3524	165.6	1	SNP	p	D95G	1	.	.	283	285	GGC	650	652	GGC	223;218;220	G;G;C	202;201;203	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5856	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3524	165.6	1	SNP	p	G95N	0	.	.	283	285	GGC	650	652	GGC	223;218;220	G;G;C	202;201;203	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1570	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1295	120.0	1	SNP	p	G45D	0	.	.	133	135	GGC	535	537	GGC	192;188;187	G;G;C	183;179;177	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	858	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1269	67.3	0	.	n	.	0	A197.	DEL	197	197	A	676	676	A	208	A	194	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6174	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2881	212.8	1	SNP	p	D86N	0	.	.	256	258	GAC	473	475	GAC	245;248;251	G;A,G;C	231;227,1;236	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6174	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2881	212.8	1	SNP	p	R87I	0	.	.	259	261	CGT	476	478	CGT	250;249;248	C;G;T	238;234;232	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6174	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2881	212.8	1	SNP	p	S87R	1	.	.	259	261	CGT	476	478	CGT	250;249;248	C;G;T	238;234;232	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6174	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2881	212.8	1	SNP	p	R87W	0	.	.	259	261	CGT	476	478	CGT	250;249;248	C;G;T	238;234;232	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6174	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2881	212.8	1	SNP	p	S88P	0	.	.	262	264	TCC	479	481	TCC	247;246;245	T;C;C	231;234;232	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4132	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2637	155.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1469	1471	GGC	214;214;213	G;G;C	195;197;194	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1224	1226	GCC	209;213;213	G;C,T;C	200;204,1;205	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1227	1229	ATG	214;213;213	A;T,G;G	206;204,1;205	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1239	1241	ACC	214;213;211	A;C;C	203;203;200	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1239	1241	ACC	214;213;211	A;C;C	203;203;200	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1740	1742	ACC	214;216;214	A;C;C	191;202;200	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1794	1796	GCG	210;209;207	G;C;G	188;190;189	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1794	1796	GCG	210;209;207	G;C;G	188;190;189	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1917	1919	GGT	202;199;200	G;G;T	182;180;177	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1926	1928	AGC	192;191;189	A;G;C	174;172;172	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4038	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2368	169.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1944	1946	CCG	167;165;156	C,G;C,G;GCCC,GCCCC	129,5;126,1;112,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6402	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3295	193.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1782	1784	CCG	214;217;220	C;C;G	188;207;195	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2146	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1737	122.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	520	520	C	137	C	124	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3414	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1554	217.4	1	SNP	p	G120K	1	.	.	358	360	AAG	609	611	AAG	267;265;265	A;A;G	247;248;243	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3414	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1554	217.4	1	SNP	p	A121N	1	.	.	361	363	AAC	612	614	AAC	265;265;265	A;A;C	247;250;247	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3414	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1554	217.4	1	SNP	p	N121D	0	.	.	361	363	AAC	612	614	AAC	265;265;265	A;A;C	247;250;247	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12550	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4823	259.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1402	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1093	127.3	1	SNP	p	V57M	1	.	.	169	171	ATG	502	504	ATG	273;274;276	A;T;G	256;259;261	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
